Resources
The company combines specialized life sciences expertise with cost-effective talent and AI solutions to support communication and strengthen connections with healthcare professionals and patients.

Epikast, a NYC-based medical organization, was founded by Vangelis Vergetis in 2022.
epikast.comCrawled Oct 14, 2026
The company combines specialized life sciences expertise with cost-effective talent and AI solutions to support communication and strengthen connections with healthcare professionals and patients.
The company is American, has its main operational hub in Greece, and partners with US- and/or EU-based pharmaceutical companies engaging patients, physicians and other healthcare providers.
New York 370 Jay St, 7th Floor Brooklyn, NY 11201
The company offers talent, a cost-effective model and AI tools to support engagement.
Epikast Inc. states that it is committed to protecting and respecting privacy. It lists its registered seat and the address and registration number of its Greek branch.
Epikast, Inc. and its branches issue these Terms of Use for the website, which provides general content about the company and its services prepared by or under its direction.
Kos Biotechnology Partners backs Epikast, a US-Greek consultancy helping pharmaceutical and biomedical firms navigate market access strategies. The firm specializes in advising companies on expanding their reach in regulated healthcare markets. This marks Kos Biotechnology Partners’ first investment.
Kos Biotechnology Partners leads a financing round for Epikast, a technology-driven company offering commercial and clinical services to the biopharmaceutical industry. This marks the firm’s first investment from its inaugural fund, which focuses on supporting life sciences ventures at various stages, from early-stage platforms to scaling mature companies.
Kos Biotechnology Partners leads the inaugural financing round for **Epikast**, a technology-driven company specializing in pharmaceutical services. The investment marks Kos’ first official commitment to a platform aimed at modernizing drug development workflows. Epikast’s solution integrates digital tools to streamline operations for biotech and pharma firms.
Kos Biotechnology Partners leads a financing round for Epikast, a life sciences company. The investment marks Kos’s inaugural deal as a newly established firm. Epikast operates in the biotechnology sector, though specific details about its technology or focus remain undisclosed.